false 0001757499 0001757499 2023-12-18 2023-12-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 18, 2023

 

SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41488   82-5089826

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

 

(240) 430-4212

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock $0.00001 per share   SHPH   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On December 18, 2023, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), held its annual meeting of shareholders (the “Annual Meeting”) to vote on the following matters:

 

1. Election of Directors.

 

All of the following six nominees were elected to the Company’s board of directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.

 

Nominee  For   Against   Withheld  

Broker

Non-Votes

 
Anatoly Dritschilo, MD   7,823,591          -    360,473           - 
Milton Brown, MD, PhD   7,841,329    -    342,735    - 
Chris Senanayake, PhD   7,823,607    -    360,457    - 
Steven Richards   7,826,170    -    357,894    - 
Joshua Schafer   7,823,527    -    360,537    - 
Bette Jacobs, PhD   7,823,624    -    360,440    - 

 

2. Ratification of the Company’s Independent Auditors.

 

Shareholders ratified the appointment of FORVIS LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023, in accordance with the voting results below.

 

For   Against   Abstain   Broker Non-Votes 
10,791,925    32,369    185,622              - 

 

3. Approval of the Company’s Executive Compensation.

 

Shareholders approved (on an advisory basis) the Company’s executive compensation, in accordance with the voting results below.

 

For   Against   Abstain   Broker Non-Votes 
7,807,163    375,059    1,842                  - 

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 19, 2023  
     
SHUTTLE PHARMACEUTICALS HOLDINGS, INC.  
     
By: /s/ Michael Vander Hoek  
Name: Michael Vander Hoek  
Title: Chief Financial Officer  

 

 

v3.23.4
Cover
Dec. 18, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 18, 2023
Entity File Number 001-41488
Entity Registrant Name SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Entity Central Index Key 0001757499
Entity Tax Identification Number 82-5089826
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 401 Professional Drive
Entity Address, Address Line Two Suite 260
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20879
City Area Code (240)
Local Phone Number 430-4212
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock $0.00001 per share
Trading Symbol SHPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false

Shuttle Pharmaceuticals (NASDAQ:SHPH)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Shuttle Pharmaceuticals Charts.
Shuttle Pharmaceuticals (NASDAQ:SHPH)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Shuttle Pharmaceuticals Charts.